4D Molecular Therapeutics (FDMT) News Today $6.25 +0.11 (+1.73%) As of 12:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Wellington Management Group LLP Purchases 70,192 Shares of 4D Molecular Therapeutics, Inc. $FDMTSeptember 3 at 3:56 AM | marketbeat.com4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA ReadinessSeptember 2 at 8:00 AM | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss RatingsSeptember 1 at 2:11 AM | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comFY2025 EPS Estimates for FDMT Decreased by Cantor FitzgeraldAugust 17, 2025 | marketbeat.comChardan Capital Has Weak Forecast for FDMT FY2025 EarningsAugust 17, 2025 | marketbeat.comHC Wainwright Brokers Lower Earnings Estimates for FDMTAugust 16, 2025 | marketbeat.comQ3 EPS Forecast for 4D Molecular Therapeutics Cut by AnalystAugust 16, 2025 | marketbeat.com4DMT Announces New Employment Inducement GrantsAugust 15, 2025 | globenewswire.comBrokers Offer Predictions for FDMT FY2027 EarningsAugust 15, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 15, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $38.00 by Analysts at Roth CapitalAugust 13, 2025 | marketbeat.com4D Molecular Therapeutics' (FDMT) "Buy" Rating Reiterated at Chardan CapitalAugust 13, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Posts Earnings Results, Misses Estimates By $0.29 EPSAugust 12, 2025 | marketbeat.com4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement LandscapeAugust 12, 2025 | msn.com4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 11, 2025 | finanznachrichten.de4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 11, 2025 | finance.yahoo.com4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesAugust 11, 2025 | globenewswire.com4D Molecular Therapeutics (FDMT) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.com4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | globenewswire.comFederated Hermes Inc. Increases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)August 4, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at Chardan CapitalAugust 2, 2025 | marketbeat.com4D Molecular Therapeutics stock soars after positive DME trial resultsAugust 2, 2025 | investing.comAssessing 4D Molecular Therapeutics: Insights From 5 Financial AnalystsAugust 2, 2025 | benzinga.com4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory UpdateJuly 31, 2025 | globenewswire.comDecheng Capital LLC Sells 64,485 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)July 30, 2025 | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)July 30, 2025 | marketbeat.com4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina SpecialistsJuly 24, 2025 | globenewswire.comWeiss Ratings Reiterates "Sell (D-)" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)July 14, 2025 | marketbeat.com4DMT Announces New Employment Inducement GrantsJuly 11, 2025 | globenewswire.com4D Molecular Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:FDMT | BenzingaJuly 6, 2025 | benzinga.comWhat 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics - 4D Molecular Therapeutics (NASDAQ:FDMT) - BenzingaJuly 5, 2025 | benzinga.com4D Molecular Therapeutics Inc News (FDMT) - Investing.comJuly 3, 2025 | investing.comChardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)July 3, 2025 | marketbeat.com4D Molecular to layoff about 25% of workforceJuly 2, 2025 | msn.com4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage ExecutionJuly 2, 2025 | globenewswire.comWeiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)June 28, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 25, 2025 | marketbeat.comCantor Fitzgerald Estimates FDMT FY2026 EarningsJune 11, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Two Sigma Advisers LPJune 3, 2025 | marketbeat.comTwo Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)June 3, 2025 | marketbeat.comBank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)June 3, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 1, 2025 | marketbeat.comVoloridge Investment Management LLC Reduces Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 31, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comMillennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 28, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss RatingsMay 28, 2025 | marketbeat.com4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progressMay 27, 2025 | investing.comDeutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 26, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)May 26, 2025 | marketbeat.com Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FDMT Media Mentions By Week FDMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.960.96▲Average Medical News Sentiment FDMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼44▲FDMT Articles Average Week Get the Latest News and Ratings for FDMT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for 4D Molecular Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PAHC News ABCL News EVO News TLRY News XERS News PGEN News ELVN News COLL News CVAC News PHVS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
